CREBBP and cancer: CREBBP polymorphisms were significantly more frequent in iCCA patients (50.0%) than in OV-infected individuals (30.0%) and healthy controls (30.8%) (P = 0.003), with homozygous mutations conferring the highest cancer risk (OR = 6.43, 95% CI: 1.70-24.31).